SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 13, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3d 7h ago
Insider cluster: 2 insiders, $2.8M total
Actionable Insight • Neutral

The CEO's sale was pre-planned under 10b5-1 and the director's sale followed option exercises, both small relative to market cap. No bearish signal from these trades; monitor next 8-K for any change in insider selling patterns.

DirectionNeutral
Confidencehigh
Horizondays

Drugs in focus

MIRM drug pipeline →

brelovitug

▲ Bullish Named in this insider cluster
Impact
Phase
Phase 3 (completed)
Time to market
Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
Next catalyst
BLA filing · H1 2027

What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two Mirum insiders sold a combined $2.83M in open-market sales within a week of the company reporting strong Q3 results and raising guidance. CEO Peetz sold $1.80M under a 10b5-1 plan; Director Brege sold $1.03M without a plan after exercising options. The sales total 0.05% of market cap, below the 0.1% materiality threshold, and the CEO's plan sale is routine.

Key Financial Metrics

Direction
selling
Total Value
$2.8M
Insiders
2

Key Facts

  • CEO Christopher Peetz sold 20,000 shares at $90.00 for $1.80M under a 10b5-1 plan on 2026-11-04
  • Director Laura Brege sold 10,907 shares at $94.05 for $1.03M (no 10b5-1 plan) on 2026-11-11
  • Brege also exercised 14,167 shares at $0 and 14,167 shares at $16.71 on the same day
  • Total open-market sales: $2.83M, representing 0.05% of $6.2B market cap
  • Q3 2026 net product sales were $185.7M (+39.6% YoY) and full-year guidance raised to $715M-$720M
  • FDA approval for ATEBRIOZ (zilurgisertib) in FOP was received

Financial Impact

Insider sales of $2.83M, 0.05% of market cap

insider ownership

Risk Factors

  • Director Brege sold without a 10b5-1 plan, which could indicate personal liquidity needs
  • Insider sales following strong earnings may raise questions if they accelerate

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MIRM-1794606926144

Track record

27 reports on MIRM

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Neutral 3/10 Viewing Entry $93.54 Now $91.58 −2.10% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
  4. Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  7. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
  9. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
  10. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
Showing 10 of 27

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026